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Abstract 
 
Transdermal drug delivery system can be described as desecrate and independent type of dosage form deliver the 
drug by controlled manner when applied to skin. Patches of Timolol Maleate was prepared by solvent casting 
technique. Timolol maleate is an antihypertensive drug having λmax 294 nm. Solid lipid nanoparticles (SLN) of 
Timolol maleate was prepared using microwave assisted microencapsulation technique by using stearic acid, tween 
20 and PEG 400. Transdermal patches were prepared using different grades of HPMC i.e. HPMC K4M, HPMC 
K15M, HPMC 50 cps HPMC K100M and cellulose acetate and different percentage of glycerine. Final 
formulation prepared by HPMC 50 cps. Drug diffusion study performed by using modified KesharyChien 
Diffusion Cell. Rat skin used as membrane for diffusion. Prepared patches examined for skin irritation and 
antihypertensive study. Anti- hypertensive activity performed by using BioPack instrument for blood pressure 
measurement. Stability studies performed at 40°C/75% RH, and 25°C/60% RH conditions. The physical stability 
of Timolol Maleate based transdermal patches proved unchanged after storage up to 3 months. Final prepared 
patch having good tensile strength, folding endurance, weight variation and drug diffusion as 91.75% in a period of 
24 hrs. 
 
Keywords: Patch, SLN, drug diffusion, anti-hypertensive, Keshary Chien Diffusion Cell.  
Introduction 
 
The development of a novel delivery system for 
existing drug molecules not only improves the drugs 
performance in terms of efficacy and safety but also 
improves patient compliance and overall therapeutic 
benefit to a significant extent. Consequently, much 
effort has been put into the development of strategies 
that could improve the patient compliance with new 
modes of application[1]. A drug is administered to 
eliminate a diseased state in living system to achieve 
this objective; it should be available in the system at a 
certain minimal concentration for a specified period 
of time. During the past 20 years, advances in drug 
formulations and innovative routes of administration 
have been made.  
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Our understanding of drug transport across tissues has 
increased. While topical products or drug delivery 
systems have been used for centuries for the treatment 
of local skin disorders, the use of the skin as a route 
for systemic drug delivery is of relatively recent 
origin. These changes have often resulted in improved 
patient adherence to the therapeutic regimen and 
pharmacologic response [2]. The administration of 
drugs by transdermal route offers the advantage of 
being relatively painless. The appeal of using the skin 
as a portal of drug entry lies in ease of access, its huge 
surface area, and systemic access through underlying 
circulatory and lymphatic networks and the 
noninvasive nature of drug delivery. Delivery of drugs 
through the skin for systemic effect, called 
transdermal delivery was first used in1981, when 
Ciba- Geigy marketed Transderm V (present day 
marketed as Transderm Scop) to prevent the nausea 
and vomiting associated with motion sickness. 
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 Throughout the past 2 decades, the transdermal patch 
has become a proven technology that offers a variety 
of significant clinical benefits over other dosage 
forms. It constitutes a new trend in controlled delivery 
system and has opened new scientific horizon in 
innovations[3]. The delivery of drugs transdermally 
(through the skin) provides several important 
advantages over traditional oral and intravenous 
delivery routes. Transdermally delivered drugs avoid 
the risk and inconvenience of intravenous therapy, 
usually provide less chance of an overdose or 
underdose, allow easy termination, and permit both 
local and systemic treatment effects. 
Currently there are 11 drug molecules: fentanyl, 
nitroglycerin, estradiol, ethinyl estradiol, 
norethindrone acetate, testosterone, clonidine, 
nicotine, lidocaine, prilocaine, and scopolamine 
available on the United State market. Two new, 
recently approved transdermal patch products (a 
contraceptive patch containing ethinyl estradiol and 
norelgestromin, and a patch to treat overactive 
bladder, containing oxybutynin) should help to 
expand the US transdermal market.  Hypertension is a 
common disorder that, if not effectively treated results 
in a greatly increased probability of coronary 
thrombosis, strokes and renal failure. Until about 
1950, there was no effective treatment, and the 
development of antihypertensive drugs, which restore 
healthy life expectancy, has been a major therapeutic 
success story. Physiology mechanisms that control 
arterial blood pressure and shows sites at which 
antihypertensive drugs act. The main systems include 
the sympathetic nervous system, the renin-
angiotensin-aldostrone system and tonically active 
endothelium-derived autocoids[4]. 
Carvedilol competitively blocks a1 b1b2 
adrenoreceptors and widely used in the management 
of Hypertension. The low bioavailability (about 20%) 
due to extensive hepatic first pass metabolism 
associated with oral route can be avoided by 
transdermal administration. The drug has a short half 
life and hence requires more frequent dosing by the 
oral route. A prolonged duration of action can be 
possible with a single application of transdermal film. 
The objective of the proposed study is to formulate 
transdermal films of Carvedilol and to study the 
release kinetics of drug with a view to prevent its first 
pass metabolism and to achieve a controlled drug 
release with improved bioavailabiity and better 
patient compliance. 
Material and method 
Timolol Maleate (TM) was generously gifted by 
Gangwal Pharmaceuticals, Mumbai, India. Stearic 
acid was gift sample of Chandri Wax Specialities 
Private Limited, Mumbai. Tween 20 and PEG 400 
was purchased from Fine Chemicals, Canada. 
HPMCK 100M was gifted by colorcon Asia Pvt. 
Ltd., All aqueous solutions were prepared using Milli 
Q/Elix water (Millipore, Moscheim Cedex, France). 
All other chemicals used were of analytical grade. 
Preformulation study 
The active material Timolol Maleate (TM) was 
generously gifted by Gangwal Pharmaceuticals, 
Mumbai, India and was observed for physical 
appearance. The absorbance maxima was determined 
by using UV-Visible Spectrophotometer. Melting 
point of Timolol maleate was determined by the 
capillary method using digital melting point 
apparatus.The calibration curve was prepared in pH 
6.4 and 1% Tween 20. It was prepared to carry out the 
drug release medium in the dissolution study as it 
mimics the transdermal condition of the body. For the 
preparation of standard, plot of TM in pH 6.4 and 1% 
Tween 20 used. In this, the drug was firstly 
solubilized in 1% Tween 20 and after complete 
solubilized the volume was made up to 100 ml with 
buffer solution pH 6.4 in 100 ml volumetric flask to 
yield the solution of concentration 100 μg/ml. From 
the above standard stock solution, further aliquots 
were diluted to get the working standard solutions i.e. 
 0, 2, 4, 6, 8, 10 μg/ml were made in triplicate to 
prepare a calibration plot of the drug in pH 6.4 and 
1% Tween 20 for drug release study. The absorbance 
of further aliquots was taken at λmax 294 nm[5] 
Formulation of Solid-Lipid Nano Particle of 
Timolol Maleate 
Preparation of Drug Loaded SLN of TM 
The SLNs were prepared by a novel microwave-
assisted micro-emulsion technique using Discover SP 
– Microwave Synthesizer (model No.: 909155) with 
explorer SP (model no. 909505) and 10 ml reaction 
vials were used to carry out present reactions.  The 
microwave conditions were set during the preparation 
of SLNs using Synergy™ software. The “Fixed 
Power Control” method was chosen for preparation of 
SLNs. This option allows for control and monitoring 
of the microwave conditions during the preparation of 
SLNs. The fixed power control option applies the 
desired maximum power until the temperature set 
point is reached after which the feedback loop 
modulates the amount of power to maintain the 
temperature set point. Accurately weighed quantities 
of ingredients (i.e. lipid, surfactant and water) were 
taken in a 30 mL thick walled Pyrex reactor tube, 
tightly sealed with a septa cap and heated in the 
microwave system with constant stirring. Here Stearic 
acid were used for preparing SLN. Tween 20 and 
PEG 400 was used as a surfactant and cosurfactant 
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[6]. The microwave temperature set point was 80 - 
85ºC (above the melting point of stearic acid) with 
microwave power not exceeding 20 W. A continuous 
supply of cooling gas (nitrogen) and the self-tuning 
capability in the microwave cavity maintained the 
reactor tube at the temperature set point of 80 - 85ºC 
for 10 min. The software allows the user to release the 
reaction product at elevated temperatures. The release 
temperature was set above the melting point of stearic 
acid. This process constitutes a single-pot synthesis of 
an o/w micro-emulsion, which is then cooled to form 
an SLN. The prepared and optimized TM loaded SLN 
was subjected for morphological study using optical 
microscopy. The optimized formulation was 
evaluated for particle size and size distribution using 
the Malvern Zetasizer The sample was diluted 100 
times with the double distilled water before analysis 
and stirred as well. Then, the sample was poured into 
the sample holder and analysed at 25°C temperature 
and 90°C scattering angle[7].  
Percent entrapment efficiency of TM in the optimized 
SLN was carried out by dispersing the weighed 
quantity of the formulation in buffer pH of 6.4 (100.0 
mL) [8]. Initially, the SLNs were dispersed in buffer 
pH of 6.4 followed with placing overnight 
undisturbed. Then, it was completely stirred (15 mins) 
followed with sonication (probe ultrasonication) to 
extract the drug. Insoluble matters (if any) were 
centrifuged at 5500 rpm for 15 mins [9]. The 
supernatant (0.5 mL) was withdrawn followed with 
membrane filtering (membrane filter, Millipore 
Mumbai, India) and diluted with buffer pH of 6.4 (2.5 
mL) before assessment. Sample was then analysed 
using UV-Vis spectrophotometer at λmax (294 nm). The 
assessment was carried out in triplicate to find mean 
value. The entrapment efficiency of the drug in the 
formulations was calculated using the reported 
formula, % Entrapment efficiency =  
(Total amount of drug – free drug in supernatant) / 
Total amount of drug. 
Preparation of SLNs Transdermal Patches 
Transdermal patches containing Timolol Maleate 
were prepared by solvent casting technique 
employing mercury as substrate. Different 
formulations were formulated using different grades 
of HPMC i.e. HPMC K4M, HPMC K15M, HPMC 50 
cps HPMC K100M and cellulose acetate, different 
percentage of glycerine and 100mg of optimized 
nanoparticles. The prepared solution was poured into 
glass petri dishes of 25 cm2 area and dried at room 
temperature. After 12 h, the patches were cut in 5 cm2 
area and packed in aluminium foil until used. Casting 
solutions were prepared by dissolving appropriate 
polymers, plasticizer in suitable vehicle using 
magnetic stirrer. The mixture was stirred continuously 
in such a manner that evaporation of solvent was 
minimum. 100mg of optimized nanoparticles was 
added slowly to the solution and dissolved by 
continuous stirring for 30 minutes. For the 
formulation of films, mercury was used as the 
backing membrane. Mercury was spread uniformly on 
a glass Petri dish. The mould was kept on a mercury 
surface. About 4 ml of the solution was poured on the 
mercury. The rate of evaporation was controlled by 
inverting the funnel over the mould. After 2 hours, the 
dried patches were cut into 2.2 cm diameter, wrapped 
in aluminium foil and stored over fused calcium 
chloride in a desiccator at room temperature for 
further use. 
Characterization of Transdermal Patches 
Physicochemical Properties of Patches 
The patches were evaluated for the following 
physicochemical properties[10]. 
Weight Variation 
Uniformity of weight was determined by weighing 
five matrices of each formulation. After each film unit 
was weighed individually on a digital balance, the 
average weight of film was taken as the weight of the 
film[11]. 
Thickness 
The thickness of the patch was measured at five 
different points using a digital micrometer and 
average thickness was recorded[12]. 
Percentage Moisture Absorption   
The  films were  weighed  accurately  and  placed  in  
the desiccator  containing 100 ml  of  saturated 
solution of aluminium chloride, which maintains 
79.50% RH. After 3 days, the films were taken out 
and weighed. The percentage moisture absorption was 
calculated using the formula[13].  
Percentage of moisture absorption =  
                       Final weight- Initial weight x 100 
                                   Initial weight 
Water Vapour Transmission Rate  
Glass vials of 1.6 cm and area of 2 cm2 were used as 
transmission cells. About 1 g anhydrous calcium 
chloride was placed in the cells and the respective 
polymer film was fixed over the brim. The cells were 
accurately weighed and kept in a closed desiccator 
containing saturated  solution  of  potassium chloride to 
maintain a humidity of 84% [14]. The cells were taken 
out and weighed after 72 h of storage.  
Folding Endurance 
Folding endurance of the film was determined 
repeatedly by folding a small strip (2 cm × 2 cm) at 
the same place until it breaks. The number of times 
the film can be folded at the same place without 
breaking gives the value of folding endurance[15]. 
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Tensile Strength 
A small film strip (2 cm × 2 cm) was cut on a glass 
plate with a sharp blade. One end of the film was 
fixed between adhesive tapes to give support to the 
film when placed in the film holder. Another end of 
the film was fixed between the adhesive tapes with a 
small pin sandwiched between them to keep the strip 
straight while stretching. A thread was tied to this 
hook, passed over the pulley and a small pan attached 
to the other end to hold the weights. To determine 
tensile strength, the film was pulled by means of a 
pulley system. Weights were gradually added to the 
pan to increase the pulling force till the film was 
broken. The elongation was determined by recording 
the distance traveled by the pointer before break of 
the film on the scale[10]. 
Content Uniformity 
The formulations were dissolved in 10 ml phosphate 
buffer pH 7.4 and stirred for 30 minutes. The 
resulting solutions were quantitatively transferred to 
volumetric flasks, and dilute up to 50 ml with pH 7.4 
phosphate buffer. The resulting solutions were filtered 
and analysed for Timolol Maleate content at 294 nm 
in UV spectrophotometer. The average reading of 
three patches was taken as the content of drug in one 
patch[16].  
In-Vitro permeation study 
A Keshary Chien Cell was used for evaluation drug 
permeation profiles across cellophane membrane. 
Phosphate buffer pH 7.4 (50 ml), was used as a 
receptor medium was filled in the diffusion cell. It 
was placed on a magnetic stirrer with a Teflon bead 
placed inside for uniform distribution. The 
semipermeable membrane was mounted in such a 
way that it continuously remained in intimate contact 
with the transdermal patch in the donor compartment. 
Transdermal patch of 2.5 cm diameter was overlaid 
on the membrane/skin preparation with good contact 
and placed in between two halves of the diffusion 
cell. The top side was covered with the aluminium 
foil as backing membrane. The receptor fluid was 
agitated using magnetic stirrer at 60 rpm and 
temperature was maintained at 37 1°C. The amount 
of drug permeated into the receptor solution was 
determined by removing 1 ml of sample at hourly 
intervals for 10, 15, 20 and 24 hour. The withdrawn 
volume was replaced with an equal volume of fresh 
receptor. The absorbance noted at 294 nm[10]. 
Stability Studies of Optimized Transdermal 
Patches 
The samples were stored and tested in accordance 
with the storage conditions and the valid test method. 
The samples were taken out of the storage on the 
planned testing date.  
Experimental Animals 
Forty five Wistar albino rats in adult size of either 
sex in weight ranging from 246-255 g were obtained 
from the Institutional Animal Ethics Committee of 
Institute of biomedical and industrial research, Jaipur 
vide Approval Number IAEC/2018-07/04. They were 
kept in groups and each group consist of nine 
animals. Each group was kept in clean poly-acrylic 
cages. It was maintained for 12 hrs day and light 
cycles at an average of ambient temperature of 25± 2o 
C and 60±10% relative humidity (RH) [17].  
Table 1: The allocation of animals to various groups 
S. No. Groups Treatment given No. of Rat 
1 Group I Blank patch, as a control 9 
2 Group II               Hypertension induced  9 
3 Group III Hypertension induced + captopril (20 mg/kg/day)                                       9 
4 Group IV Hypertension induced +Prepared nano-particle formulation of TM                 9 
5 Group V Hypertension induced +Timolol maleate nanoparticles loaded Transdermal patch            9 
Skin Irritation Study 
Study performed on wistar rats for 14 days. Skin irritation study performed as the group assigned. Patches are 
applied on the backside of hairless skin of  rats for 23 ± 1 hr upto 14 days to the same skin site(Table 1).  
Table 2: The ranking of skin irritation in animals 
Ranking  Criteria 
0 No evidence of irritation 
1 Minimal erythema, barely perceptible 
2 Definite erythema, readily visible; minimal edema or minimal popular response 
3  Erythema and papules 
4 Definite edemal 
5 Erythema, edema, and papules 
6 Vesicular eruption 
7 Strong reaction spreading beyond test site 
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After 24 hrs if any type of irritation found then patch 
should be apply on other site. Each day skin was 
examine for any type of major and minor skin 
reactions as mention below scale of 0 to 7 numbers 
Evaluation of in-vivo Antihypertensive Effect 
Diverse models available, for the existent study, the 
dietary induction of hypertension in Wistar rats was 
employed using 66% w/v D-Fructose according to 
methods described by Jena et al.[18].. Each rat was 
educated and familiarized to the restrainer and 
transducer, for about 15 mins before the experiment. 
The rat was nonaggressive in a low-stress 
environment and allowed to enter the holder freely at 
least 10–15 min prior to obtaining BP measurements. 
The animal's nose was made to protrude through the 
front of the nose cone permitting for relaxed breathing 
and the tail of the animal was fully prolonged to exit 
through the rear hatch opening of the holder. The rat 
was warmed but not heated using restrainer, the room 
temperature was maintained about 32–35.4°C, reduce 
stress and the blood flow to the tail was enhanced to 
acquire a BP signal. The rat never had its head bent 
sideways or its body compressed against the back 
hatch. The animal's temperature was monitored 
throughout the experiment as the procedure suggested 
by Malkoff et al., [19]. 
Data Treatment 
From the dissolution data, dissolution rate constant 
(k), and dissolution half-life (t50%) were calculated. The 
slope and regression coefficient of % cumulative 
release versus time (Zero order release kinetics), log 
% unreleased versus time (First order release 
kinetics), CBR(Wo)-CBR(Wt) versus time (Hixson–
Crowell), % cumulative release versus time0.5 (Higuchi 
release kinetics) and log cumulative % drug release 
versus log time (Korsmeyer–Peppas) were calculated 
using MS Excel 2007 computer program[20].  
Results and discussion 
The preformulation study is a stage of product 
development during which the physicochemical 
properties of drug substance are characterized. Timolol 
maleate absorption maxima were found to be 294 nm. 
As the observed melting point (2000C) was found to be 
in similar range as that of reported value (202.5 0C). 
The calibration curve of TM in water was found to be 
linear in the concentration range of 2 mcg/ml to10 
mcg/ml with R2=0.993. The calibration curve of TM in 
phosphate buffer saline pH 6.4 was found to be linear 
in the concentration range of 2mcg/ml to10mcg/ml 
with R2=0.992.  
Formulation of Solid-Lipid Nano Particle of 
Timolol Maleate 
In the microwave-assisted method, preparation of the 
microemulsion is a “single-pot” step wherein all the 
composition ingredients are heated together in 
controlled microwave reaction conditions.  
Morphological Assessments 
In order to visualize the architecture of the surface of 
the SLNs of the TM, SEM confirmed uniform surface 
maintained throughout the preparation.  
 
Fig. 1: Scanning electron microscopy (SEM) images of TM loaded SLNs 
 
Particle Size and Distribution Studies 
The results of particle size analysis of SLNs confirmed the size of the developed optimized formulation.  
Table 3: Particle size distribution and Zeta potential by Malvern Instrument 
 
Formulation Size Distribution(nm) Mean Intensity(%) Zeta potential(mV) 
F9 122.6 67.3% -40.3 
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Fig 2: Particle size distribution and Zeta potential of SLNs of TM 
Percent Drug Entrapment Efficiency Study  
Entrapment efficiency of the SLNs was determined 
by lysing the SLNs in a pH 6.4 PBS and further with 
Triton-X-100. Regression equation for the standard 
plot of TM in pH 6.4 PBS – Y= 0.007X and Dilution 
Factor = 50. Drug content and encapsulation 
efficiency are important parameters to evaluate the 
drug content of SLNs. Drug content of the TM loaded 
SLNs  was found to be 72.5%.  
Characterization of Optimized Formulations  
Various physical evaluations like thickness 
uniformity, weight variation, tensile strength, folding 
endurance of the optimized transdermal patches were 
performed according to the methods given in the  
In-vitro permeation studies 
In vitro permeation studies of the optimized 
formulations were performed using modified 
Keshary-Chien cell. 
 
Fig. 3:  Plot of Cumulative percent permeated versus time from formulations P1-P12 
 
Table 4:  Physicochemical properties of optimized formulations 
F.C. 
Weight 
Variation 
(mg) 
%MA %ML WVTR* 
Thickness 
(mm) 
Tensile 
Strength 
(kg/mm2) 
Folding 
Endurance 
P1 44.21±0.12 3.92±0.14 4.93±0.432 0.237±.042 0.58±0.00 0.479±0.004 1583±2.32 
P2 43.93±1.35  3.94±0.31 4.78±0.786 0.321±0.045 0.48±0.001 0.434±0.008 1498±2.13 
P3 43.22±0.10  3.82±0.13 4.83±0.423 0.217±.043 0.54±0.00 0.429±0.004 1563±1.52 
P4 41.63±1.35  3.49±0.33 4.87±0.768 0.312±0.045 0.43±0.001 0.443±0.008 1457±1.84 
P5 45.25±0.92  4.01±0.21 5.93±0.291 0.189±0.019 0.51±.001 0.356±0.009 1567±1.75 
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P6 40.12±1.57  4.98±0.37 6.42±0.385 0.347±0.09 0.63±0.00 0.518±0.004 1520±2.22 
P7 43.83±0.46  4.42±0.24 3.86±0.629 0.411±0.065 0.69±0.00 0.464±0.003 1479±1.96 
P8 44.93±0.80  3.67±0.49 4.67±0.354 0.284±0.029 0.68±0.001 0.452±0.006 1543±2.23 
P9 46.91±0.49  3.30±0.19 3.12±0.344 0.137±.012 0.65±0.002 0.587±0.001 1614±2.32 
P10 41.87±0.74  3.11±0.24 3.34±0.621 0.375±0.035 0.42±0.001 0.401±0.005 1321±2.54 
P11 40.11±0.10  3.12±0.14 3.93±0.423 0.217±.024 0.48±0.00 0.429±0.004 1383±1.73 
P12 38.93±1.53  3.24±0.13 3.87±0.466 0.221±0.025 0.49±0.001 0.443±0.006 1398±1.93 
Indicates values are average of three observations.  
 
Fig 4: Plot of Log Cumulative Percent Drug Retained Versus Time formulations P1-P12 (First Order 
Kinetics) 
Table 5: In-Vitro permeation profile of Timolol Maleate formulation P1 to P12 
 
Ti
me 
Cumulative % Drug Permeated 
P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 
0 
0.00±
0.0 
0.00±
0.0 
0.00±
0.0 
0.00±
0.0 
0.00±
0.0 
0.00±
0.0 
0.00±
0.0 
0.00±
0.0 
0.000.
0 
0.00±
0.0 
0.00±
0.0 
0.00±
0.0 
1 
7.20±
0.45 
7.56±
0.42 
8.95±
0.41 
5.37±
0.34 
6.24±
0.34 
6.79±
0.36 
7.25±
0.42 
8.04±
0.41 
9.79±
0.23 
5.15±
0.42 
6.15±
0.47 
5.95±
0.52 
2 
8.41±
0.34 
9.44±
0.42 
10.33
±0.41 
7.66±
0.24 
8.23±
0.34 
8.08±
0.38 
8.66±
0.34 
9.29±
0.38 
12.37
±0.35 
6.12±
0.41 
6.90±
0.52 
7.29±
0.42 
3 
9.50±
0.35 
9.98±
0.45 
11.58
±0.35 
9.08±
0.41 
9.22±
0.41 
9.50±
0.42 
10.12
±0.34 
10.41 
±0.38 
13.62
±0.38 
7.23±
0.42 
7.53±
0.36 
8.50±
0.41 
4 
11.33
±0.41 
12.43
±0.38 
13.12
±0.41 
10.50
±0.40 
10.66
±0.42 
10.91
±0.41 
11.58
±0.38 
12.29
±0.40 
15.20
±0.36 
7.25±
0.40 
7.95±
0.28 
9.95±
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±0.42 ±0.44 ±0.42 ±0.43 ±0.46 ±0.54 ±0.42 ±0.48 ±0.42 ±0.47 ±0.43 ±0.52 
15 
35.08
±0.48 
36.23
±0.42 
41.58
±0.48 
32.62
±0.44 
35.25
±0.42 
36.04
±0.46 
39.54
±0.42 
40.52
±0.41 
46.25
±0.48 
30.25
±0.37 
30.75
±0.43 
31.87
±0.48 
20 
42.66
±0.42 
53.72
±0.48 
61.91
±0.45 
50.50
±0.48 
52.34
±0.43 
53.33
±0.58 
57.00
±0.54 
58.16
±0.42 
69.41
±0.41 
41.75
±0.46 
42.17
±0.48 
45.91
±0.45 
24 
58.41
±0.48 
68.42
±0.43 
68.66
±0.42 
59.47
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62.41
±0.54 
66.41
±0.48 
73.16
±0.42 
74.41
±0.43 
91.75
±0.48 
51.12
±0.58 
51.31
±0.42 
53.33
±0.48 
 
 
Fig 5: Plot of Log cumulative percent drug permeated versus log time formulations P1-P12 (Korsmeyer 
peppas model) 
 
Fig 6: Plot of Cumulative percent drug permeated versus square root of time formulations P1-P12(Higuchi 
model) 
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In-Vivo Skin Irritation Study 
Results revealed that as hypertension induced rats 
along with prepared nano-particle formulation of TM 
is a skin irritant. When rats was treated with SLNs 
along  it produce irritation with minimal erythema 
after 10 days and definite erythema, readily visible 
edema was produce after 12 days.Compared with this 
both the placebo and optimized batch was not show 
any type of irritation up to 10 days after that there was 
little erythema found with light redness at the site of 
application.  
In-Vivo Anti-hypertensiveStudy     
The dietary induction of hypertension in Wistar rats 
was employed using 66% w/v D-Fructose according 
to methods described by Jena et al. (2013).  
Table 6: Measured Systolic blood pressure of different groups of rat 
Sr. No.  Group  0th day 7th day 14th day 
1 Control  111±2.11 110±3.25 106±3.77 
2 Disease control  108.2±2.25 124.5±3.11 135.5±2.24 
3 Standard  109.5±1.75 114.5±2.42* 111.6±3.06* 
4 Test I Patch  112.6±2.46 119.4±2.25 118.5±3.60* 
5 Test II SLN Patch 110.5±2.35 115.2±3.15 113.6±2.60* 
Table 7: Measured Diastolic blood pressure of different groups of rat 
Sr. No.  Group  0th day 7th day 14th day 
1 Control  77.2±2.50 78.5±2.85  79.6±2.30 
2 Disease control  79.2±3.15 89.8±3.47   93.2±3.25 
3 Standard  78.6±2.85 82.3±2.11 80.2±3.10* 
4 Test I Patch  76.8±2.01 86.2±2.50 84.4±2.78* 
5 Test II SLN Patch 78.2±3.22 85.3±3.10 82.5±2.15* 
*Significant P‹0.05 as compared to disease control  
 
     
Fig. 7: Graphs showing Systolic blood pressure of rats 
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                Fig. 8: Graphs showing Diastolic blood pressure of rats 
Results revealed that as hypertension induced rats 
along with prepared nano-particle formulation of TM 
is a non skin irritant.  
Stability Studies 
Stability studies of the transdermal patches were 
carried out at 40 ±20C and 75 ± 5% RH for three 
months to assess their potential utility. After storage 
for three months, the transdermal patches were 
subjected to any change in physical appearance and 
drug content studies. Results of the stability study 
showed that there was no marked difference in 
physical appearance and drug content of patches 
before and after storage. 
Conclusion 
Novel nanoparticle based transdermal formulation 
was developed for the hypertension. In this system, 
drug release profiles were controlled by using both 
natural as well as synthetic polymers. The triple fold 
release was aimed to target drug delivery to the 
hypertension patients followed by transdermal drug 
delivery with preventing the burst release of drugs in 
the stomach and small intestine.  Timolol Maleate 
was selected due to less skin irritation, low dose, short 
plasma half life, low molecular weight and its 
partition coefficient value was in the range. 
Identification, solubility, partition-coefficient of drug 
were performed. FTIR technique has been used to 
study the physical and chemical interactions between 
drug and excipients used. It has been observed that 
there was no chemical interaction between drug and 
polymer used. Calibration curve of Timolol Maleate 
was prepared in phosphate buffer pH 7.4 at 294 nm 
using UV spectrophotometer. SLNs formulations 
were evaluated for different parameter like 
microscopy, particle size, shape, drug content, ex vivo 
release study, zeta potential etc. All the formulations 
were optimized to get the best entrapment efficiency. 
From the above observation it can be concluded that 
sonication is essential tool for the preparation of 
SLNs. The selection of an optimized formulation was 
carefully done after performing preliminary particle 
characteristics measurements. Use of natural 
permeation enhancer with various grades of HPMC 
(50 cps and K100M) and ethyl cellulose in the 
formulation of transdermal patch of Timolol Maleate 
that leads to superior properties. HPMC 50 cps has 
been selected because it was a non-toxic polymer 
which provides transparent patches with good 
organoleptic properties. In preliminary studies, drug 
free transdermal patches were prepared by using 
different grades of HPMC and ethyl cellulose and 
concentration of plasticizer was varied. On the basis 
of physical appearance and uniform thickness, the 
concentration and grades of HPMC 50 cps were 
selected. These transdermal patches were evaluated 
for physical characterization like weight variation, 
thickness, percentage moisture absorption, percentage 
moisture loss, water vapour transmission rate, folding 
endurance, tensile strength and content uniformity. 
The patches so formed showed satisfactory 
physicochemical properties. Further, in vitro 
permeation studies were performed by using modified 
Keshary Chien permeation cell. This study was 
conducted to investigate the effect of different 
polymers and type of permeation time profiles from 
Timolol Maleate patches. Although the drug was 
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diffused across cellophane membranes but the 
permeation profile was not satisfactory so it was 
necessary to add permeation enhancer in these 
patches. Almond oil was selected as a permeation 
enhancer. The fabricated final transdermal patches 
were subjected to in vitro permeation studies and the 
diffusion data obtained were analysed quantitatively 
to describe kinetics and mechanism of drug 
permeation from patches. The drug release from the 
formulation followed zero order drug release kinetic 
with a significant linear correlation. By employing 
Korsemeyer-Pepas model, results indicate that 
anomalous transport (0.5<n<1.0) predominated in the 
optimized formulations indicating swelling controlled 
drug permeation. By the incorporation of 4 ml of 
almond oil as permeation enhancer in optimized 
formulation the drug permeation was increase upto 
1.64 fold while the similar result was observed with 
others. Terpenes present in it enhance diffusion of 
drug by extracting lipids from stratum corneum which 
results in reorganization of lipid domain and barrier 
disruption. Outcomes of the in-vivo results have 
shown that encapsulation of TM by SLNs were 
successful in the treatment of hypertension without 
premature release of the drug. Conclusively, the 
development of a SLNs based transdermal patches 
method is a good approach for hypertension disease. 
Stability studies were performed at 40°C/75% RH, 
and 25°C/60% RH conditions. The physical stability 
of Timolol Maleate based transdermal patches proved 
to be unchanged after storage up to 3 months. 
Transdermal patch evaluated for anti hypertensive 
study and a skin irritation study. No any marked skin 
irritation observed before and after applying the 
patch.  
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